FFR-guided PCI catches up to CABG at five years in FAME 3 study

ACC, MedAxiom Collaborate on Cardiovascular Care Transformation Initiative

Recently published foundational document and AI chapter provide a framework for health systems to integrate novel paradigms of care delivery.

ACC and MedAxiom Collaborate on Major Cardiovascular Care Transformation Initiative

Recently published foundational document and AI chapter provide a framework for health systems to integrate novel paradigms of care delivery CHICAGO--(BUSINESS WIRE)--The American College of Cardiology’s (ACC’s) five-year Strategic Plan includes a maj... L'articolo ACC and MedAxiom Collaborate on Major Cardiovascular Care Transformation Initiative è un contenuto originale di 01net.

FFR-guided PCI catches up to CABG at five years in FAME 3 study

William Fearon presents FAME 3 results at TCT 2021 Five-year results of the FAME 3 trial, comparing fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) to coronary artery bypass graft (CABG) surgery in patients with three-vessel coronary artery disease, have shown no significant difference between the two strategies for a composite outcome of death, stroke or myocardial infarction (MI). Previously, PCI had failed to mee…